Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ardelyx Inc.

Modulating mineral absorption to treat GI disorders

This article was originally published in Start Up

Executive Summary

Ardelyx Inc. is designing drugs to interact with specific proteins that are found in the intestinal lining and control mineral transport. The company’s most advanced candidate, RDX5791, is meant to block sodium by selectively inhibiting NHE3, a sodium transporter on the surface of the intestinal lining. Preventing sodium absorption may increase the amount of fluid in the lumen of the gut, thus Ardelyx is developing RDX5791 as a treatment for irritable bowel syndrome with constipation.


Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts